Thyroid Cancers | Clinical

Method for Targeting RET in Thyroid Cancers and Other RET+ Advanced Cancers

May 06, 2021

In an interview with Targeted Oncology, Vivek Subbiah, MD, reviewed the data supporting selpercatinib as treatment of RET fusion-positive thyroid cancers, as well as the exploration of this agent in other RET-altered cancers.

Multiple Trial Regimens Demonstrate Efficacy for RET-Mutated Medullary Thyroid Cancer

March 31, 2021

A number of clinical trials have provided evidence of efficacy of combination regimens for the treatment of RET-mutant medullary thyroid cancer. During a virtual Targeted Oncology Case-based Roundtable event, Lori Wirth, MD, discussed the options for a 58-year-old man with RET-mutant medullary thyroid cancer.